RFCA
ADVM

R&F Capital Advisors’s Adverum Biotechnologies ADVM Stock Holding History

R&F Capital Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$45K Buy
+1,656
New +$47.1K 0.01% 652

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R&F Capital Advisors's ADVM Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Adverum Biotechnologies (ADVM) in Q1 2017: 1,656 shares worth $45K. The stake represents 0.01% of the portfolio and ranks #652 among its holdings.

75 funds tracked by Wall St. Rank hold ADVM as of Q1 2017.

  • R&F Capital Advisors held 1,656 shares of Adverum Biotechnologies worth $45K as of Q1 2017.
  • Adverum Biotechnologies was a new R&F Capital Advisors position in Q1 2017.
  • Adverum Biotechnologies made up 0.01% of R&F Capital Advisors's portfolio in Q1 2017, its #652 holding.
  • 75 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.